Philippe Gisbert has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cabergoline (Velactis®) administration at dry-off enhances milk yield in subsequent lactation of Holstein and Girolando (Gir × Holstein) cows

    by Alexandre Henryli de Souza, Philippe Gisbert, Carla Lopes de Azevedo, Alessio Valenza, Viviane Ribeiro Pinheiro Coelho, Emiliana Oliveira Santana Batista, João Paulo Nascimento Martins

    This study aimed to assess the impact of suppressing prolactin secretion at dry-off using cabergoline on subsequent lactation performance. In Experiment 1, 326 Holstein cows housed in a free-stall facility were assigned at dry-off to receive either cabergoline (5.6 mg, n = 168) or saline (n = 158). In Experiment 2, 417 Gir × Holstein (Girolando) cows in a compost barn were subjected to the same treatments. Data collected included daily milk yield (Experiment 1) or test-day milk yield (Experiment 2), somatic cell count (SCC), and incidences of retained placenta, clinical ketosis, clinical mastitis, and pregnancy by 150 days in milk (DIM). Milk production was analyzed using repeated-measures mixed models, with cow as a random effect, and binary outcomes were evaluated assuming a binomial distribution using the GLIMMIX procedure in SAS (Version 9.4). No treatment differences were observed for postpartum disease incidence or pregnancy rates by 150 DIM. However, cabergoline significantly reduced early postpartum SCC (1.57 ± 0.04 vs. 1.77 ± 0.04 log SCC; p < 0.01). Milk yield was significantly higher in cabergoline-treated cows in both experiments. In Experiment 1, cumulative milk production by 16 weeks postpartum was greater with cabergoline (4933 ± 36 kg vs. 4788 ± 38 kg; p = 0.04). In Experiment 2, cabergoline-treated cows produced more milk by 200 DIM (7395 ± 32 kg vs. 7017 ± 33 kg; p = 0.03). Treatment effects were independent of parity, dry period length, or milk yield at dry-off. In conclusion, cabergoline administration at dry-off enhanced milk production and reduced subclinical mastitis in the subsequent lactation without affecting postpartum health or fertility.

  • Open Access

    Ketoprofen as the sole initial treatment for nonsevere bovine mastitis: Efficacy and antibiotic reduction

    by V. Krömker, U. Falkenberg, N. Wente, Y. Zhang, S. Leimbach, J. Nitz, P. Gisbert, F. Nankemann

    Targeted mastitis treatment concepts are the most scientifically validated approaches to comply with the prudent use of antimicrobials. However, this approach is still a challenge for many farmers who often lack experience with it. Another option for more prudent use of antibiotics in mastitis therapy could be the initial treatment with an non-steroidal anti-inflammatory drug (NSAID) for non-severe mastitis. A randomized, multi-herd, non-inferiority study was carried out to compare 2 treatments of non-severe mastitis cases. The animals in the studied group were treated with systemic NSAID (ketoprofen (KE); KE group; n = 104), followed by antibiotic treatment only in cases without clinical improvement, while the animals in the reference group (AB group) received an intramammary antibiotic (n = 118). The study included 222 cases of non-severe clinical mastitis on 3 conventional dairy farms in Northern Germany between November 2022 and November 2023. Study outcomes were clinical cure at d 5, bacteriological cure, CM recurrence in a period of 60 d and new infection risk. Mixed logistic regression was used to analyze the effect of treatment on outcomes. The non-inferiority assumption was checked with the confidence interval of the treatment difference for clinical cure at d 5, calculating using the least squares means and their standard deviations. With regard to the clinical cure on d 5, the treatment in the KE group was inferior. Clinical cure [84.7% (100/118 and 61.5% (64/104)] and bacteriological cure [79.3% (73/92) and 61.2% (41/67)] were significantly higher in the AB group than in the KE group. The risks for recurrent cases [7.3% (8/109) and 15.7% (14/89)] were significantly lower in the AB group than in the KE group. The new infection risk did not differ significantly between the treatment groups [6.8% (8/118) in the AB group and 6.7% (7/104) in the KE group]. In 87% of the cases (n = 90) of the KE group, a subsequent antibiotic treatment was not necessary to reach clinical cure on d 5. The use of KE as the sole initial treatment for non-severe mastitis led to a reduction of antibiotic doses by 86%. Our findings revealed that systemic treatment with KE resulted in lower clinical and bacteriological cure rates, higher recurrence rates of clinical mastitis, and an elevated risk of new infections compared with the antibiotic-treated group. Nevertheless, in more than 85% of cases treated with KE, additional intramammary antibiotic treatment was unnecessary. Thus, this treatment concept represents an alternative in mastitis treatment that promoted the deliberate and selective use of antibiotics but has limitations in terms of treatment efficacy in mastitis. A targeted mastitis concept based on the identification of the bacterium involved could help to select cases to be treated with ketoprofen alone and therefore to overcome this limitation.


  • Open Access

    Efficacy and Safety of an Inactivated Phase I Coxiella burnetii Vaccine to Control Q Fever in Ruminants: A Systematic Review

    by Philippe Gisbert, Ana Hurtado, Raphaël Guatteo

    Q fever is a disease caused by Coxiella burnetii that affects many animal species and humans. In ruminants, the disease is responsible for several reproductive disorders (such as abortions, stillbirths, premature births, weak offspring, retained foetal membranes and infertility). An inactivated vaccine based on a phase I antigen of C. burnetii is available for cattle, goats and sheep. This review aims to summarise the scientific literature regarding the efficacy and safety of this vaccine to control the infection in these three domestic ruminant species. Forty-five publications and one experimental veterinary thesis reporting on experimental studies, case reports, mathematical modelling and intervention studies were selected according to the PRISMA guidelines. Although some studies lack control groups or statistical analyses, for all three species, published data show that vaccination often results in a reduction in abortions and an improvement in reproductive performance in comparison with absence of vaccination. There is also evidence, including in infected herds and animals, that vaccination is associated with a reduction in bacterial shedding, both in intensity and duration in comparison with absence of vaccination. For these reasons, in case of human outbreaks, vaccination is one of the pillars of control measures. Vaccination is generally well tolerated, despite the rare occurrence of mild, transient side-effects, such as hyperthermia and reduction in milk yield.


  • Open Access

    Coxiella burnetii and Reproductive Disorders in Cattle: A Systematic Review

    by Philippe Gisbert, Irina Garcia-Ispierto, Luis Angel Quintela, Raphaël Guatteo

    Coxiellosis or Q fever is an infectious zoonotic disease caused by the bacterium Coxiella burnetii. A systematic review using bibliographic research was carried out, and the focus was the relationship between C. burnetii infection and reproductive disorders in cattle [abortion/stillbirth/perinatal morality/weak calves (ASPW complex); retained foetal membranes (RFMs); metritis/endometritis; and infertility/sub-fertility]. The bibliographical search yielded 443 results from databases, but only 61 were deemed eligible. For each disorder, summary tables were prepared, and a scientific evidence score was calculated for each study based on four criteria to help assess the level of evidence for the impact of C. burnetii on the reproductive disorders assessed: type of publication (peer-reviewed or other); type of study (case–control/cohort or other); type of C. burnetii test (direct or indirect); and comparative statistical analysis (yes or no). In addition, summary tables also included information on the study population, country, authors and year of publication, key findings and an assessment of the evidence for an association. For the ASPW complex, RFMs, metritis/endometritis and infertility/sub-fertility, 43, 9, 8 and 19 studies provided data, respectively. On a scale of four, nearly 50% of all study citations had evidence scores of three or four. For ASPW, RFMs and infertility/sub-fertility, there is a significant body of evidence to support a deleterious role for Q fever. In contrast, for metritis/endometritis, the evidence is unclear. It is concluded that there is a substantial need for further research, particularly involving larger animal populations in more controlled settings. To provide more consistency, it is recommended that authors follow more precise definitions of reproductive parameters and more robust diagnostic methodologies.


  • Open Access

    Prevalence, Risk Factors, and Relationship between Reproductive Performance and the Presence of Antibodies against Coxiellosis in Dairy Farm Milk Tanks in the Northwest of Spain

    by Uxía Yáñez, Jacobo Álvarez, Cristina Pisón, Antía Acción, Juan J. Becerra, Antonio Jiménez, Philippe Gisbert, Pedro G. Herradón, Ana I. Peña, Alberto Prieto, et al.

    Q fever is a zoonotic disease that has been associated with reproductive problems in animals. As there is little epidemiological data regarding the distribution and risk factors of this disorder in cattle, the objective of this study was to evaluate the prevalence of Coxiella burnetii among dairy herds in the northwest of Spain, and to determine the on-farm risk factors associated with the disease and its effects on reproductive performance. Bulk tank milk (BTM) samples were collected from 262 commercial dairy herds from A Coruña, Lugo, and Pontevedra provinces. Data about location, mean age, and herd management features were obtained. A commercial indirect ELISA kit was used to determine the presence of antibodies against C. burnetii in BTM samples. The relationship between seropositivity to C. burnetii and the risk factors was checked using a Pearson’s χ2 test and a classification tree analysis. In addition, a one-way ANOVA test and the Mann–Whitney U test were used to check the impact of seropositivity to C. burnetii on reproductive performance. A total of 60.1% of the farms tested positive for coxiellosis, the herd size, the external purchase of livestock, and the geographical area were identified as the main risk factors. Conception rate and first-service conception rate were significantly lower (p < 0.05) in positive farms (37.1 and 32.9%) compared to negative farms (39.8 and 36.1%). Similarly, positive farms had significant higher incidence of endometritis (13.7% vs. 11.2%, p < 0.05). Consequently, a high seropositivity and slightly negative effects of coxiellosis on reproductive performance were observed, which intensifies the need for further research, including the identification an active infection in positive herds and the characterization of the genotype.


  • Open Access

    Cross-Neutralization between Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2 after Vaccination with a BVDV-1a Modified-Live-Vaccine

    by Geromine Grange, Marie Mindeguia, Philippe Gisbert, Gilles Meyer

    Control of Bovine Viral Diarrhea Virus types 1 and 2 (BVDV-1 and BVDV-2) involves removing persistently infected animals from the herd, ensuring the biosecurity level of the farms and vaccination for the prevention of fetal infection. Given pestiviruses high genetic and antigenic diversities, one challenge for a BVDV vaccine is to provide the broadest possible heterologous protection against most genotypes and sub-genotypes. The Modified-Live Mucosiffa® vaccine, which contains the BVDV-1 sub-genotype 1a (BVDV-1a) cytopathic Oregon C24 strain, was shown to protect fetuses of pregnant heifers against a challenge with a BVDV-1f Han strain. In this study, we tested the cross-neutralizing antibody (NA) response of 9 heifers at 28, 203- and 363-days post-vaccination with Mucosiffa® against recent and circulating European strains of BVDV-1a, -1b, -1e, -1f and BVDV-2a. We showed that Mucosiffa® vaccination generates a stable over time NA response against all BVDV strains. NA response was greater against BVDV-1a and -1b, with no significant differences between these sub-genotypes. Interestingly the NA response against the two BVDV-2a strains was similar to that observed against the BVDV-1f Han strain, which was the challenge strain used in fetal protection studies to validate the Mucosiffa® vaccine. These results suggest that Mucosiffa® vaccination provides humoral cross-immunity, which may protect against BVDV-1 and BVDV-2a infection.


  • Open Access

    QTest: A new way to easily sample, store, and ship samples to perform Q fever PCR analysis on bulk tank milk

    by Michael Treilles, Pierre Charollais, Raphaël Guatteo, Carla Azevedo, Damien Achard, Juan Munoz-Bielsa, Philippe Gisbert

    Summary: In dairy cattle at the herd level, Coxiella burnetii can be diagnosed by PCR on bulk tank milk (BTM). To facilitate the collection and shipment of BTM samples to the laboratory, we validated the use of Whatman FTA Elute Micro Cards for the conservation of BTM in 2 studies. The first study evaluated the stability of samples over time and at 2 different storage temperatures. The second compared results for BTM stored on FTA cards and raw BTM stored as is.